Quantitative and Standardized Pseudovirus Neutralization Assay for COVID-19.

Jerilyn R Izac, Edward J Kwee, Adolfas Gaigalas, Lili Wang

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

2.3field-weighted citation impact, top 16% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jerilyn R IzacBiosystem and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, USA.

Edward J KweeBiosystem and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, USA.

Adolfas GaigalasBiosystem and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, USA.

Lili WangBiosystem and Biomaterials Division, National Institute of Standards and Technology (NIST), Gaithersburg, MD, USA. lili.wang@nist.gov.

National Institute of Standards and Technology · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a global pandemic caused by the highly infectious SARS-CoV-2 virus. Efforts to combat SARS-CoV-2 infection include mass vaccination and development of monoclonal and convalescent plasma therapeutics that require precise measurements of correlative, functional neutralizing antibodies that prevent virus infection. Developing rapid, safe, easy-to-use, and high-quality neutralization assays are essential for the success of the massive effort. Here, we developed a vesicular stomatitis virus-based neutralization assay that was capable of quantifying varying degrees of neutralization in patient serum samples. This assay has two detection readouts, flow cytometry and live cell imaging. The two readout methods produced consistent values of all 50% neutralization titers, further enhancing measurement confidence on the assay. Moreover, the use of available reference standards such as the World Health Organization International Standard (NIBSC code 20/136) enables quantification and standardization of the pseudovirus neutralization assay with neutralizing antibody titers measured in International Units/mL. Quantitative and standardized neutralization assays are critical for reliable efficacy evaluation and comparison of numerous vaccines and therapeutics.

Indexed as

COVID-19Antibodies, NeutralizingAntibodies, ViralCOVID-19 SerotherapyFlow CytometryHumansImmunologic TestsNeutralization TestsSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Assay standardizationFlow cytometryHEK293-hACE2-TMPRSS2-mCherry cell lineLive cell imagingMultiplicity of infection (MOI)Neutralizing antibodiesNIBSC 20/136 (WHO IS 20/136)Pseudovirus neutralization assayQuantificationSARS-CoV-2VSV-ΔG spike pseudovirusWHO International Standard

Identifiers

PMID38526789

DOI10.1111/jmi.12269

OpenAlexW4393169407

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.